摘要
该研究基于国家知识产权局专利数据库中药复方专利,探析中药治疗心绞痛的组方规律。搜集建库至2022年11月10日符合纳入标准的中药治疗心绞痛的复方专利数据,运用Excel 2021、IBM SPSS Statistics 26.0、IBM SPSS Modeler 18.0、Cytoscape 3.9.1、Rstudio R 4.2.2.2等软件对处方数据进行数据建模、主治证候分析、用药频次分析、聚类分析、关联规则分析和数据可视化等以探究心绞痛的组方规律。最终纳入符合标准的心绞痛专利数据636项,涉及中药815味,总频次6 586次;常见的主治证候为心血瘀阻证(频次222次,频率34.91%)和气虚血瘀证(频次112,频率17.61%);用药频次排名前10位的中药有丹参、川芎、三七、黄芪、当归、红花、甘草、人参、冰片、延胡索;高频药物类别以活血化瘀药(频次1 197次,频率18.17%)、补虚药(频次809次,频率12.28%)为主;聚类分析共得到8个药物组合,其中可供临床处方与新药开发的新处方5个,对药3组;中药核心复杂共现网络筛选得到核心组合丹参-川芎-红花;关联规则分析共得到数据17条(对药组合13条,角药组合4条),常用对药组合有丹参-川芎(支持度25.79%,置信度69.49%,提升度1.30)、丹参-三七(支持度22.01%,置信度61.95%,提升度1.16),常用角药组合有丹参-川芎-黄芪(支持度10.85%,置信度73.40%,提升度1.37)、丹参-川芎-三七(支持度10.69%,置信度79.07%,提升度1.48)等。结果表明,心绞痛的基本病机为心血瘀阻、气虚血瘀,病性总属本虚标实,处方多用丹参、川芎、红花等活血化瘀药以化其标实,再配伍黄芪、当归、甘草、人参等补益药以益其正虚,其证型、病机、病性及用药与临床实际相符。同时,通过多元数据挖掘所得新复方及对药组合可为临床诊治心绞痛及新药开发提供参考与借鉴。
This study explored the medication rules of Chinese herbal compound prescriptions for the treatment of angina based on the Chinese herbal compound patents in the patent database of the China National Intellectual Property Administration.The data of eligible Chinese herbal compound patents for the treatment of angina were collected from the patent database of the China National Intellectual Property Administration from database inception to November 10,2022,and subjected to data modeling,analysis of main syndromes,medication frequency analysis,cluster analysis,association rule analysis,and data visualization by using Excel 2021,IBM SPSS Statistics 26.0,IBM SPSS Modeler 18.0,Cytoscape 3.9.1,and Rstudio R 4.2.2.2 to explore the medication rules for angina.The study included 636 pieces of patent data for angina that met the inclusion criteria,involving 815 drugs,with a total frequency of 6 586.The most common main syndromes were blood stasis obstructing the heart syndrome(222,34.91%) and Qi deficiency and blood stasis syndrome(112,17.61%).The top 10 most frequently used drugs were Salviae Miltiorrhizae Radix et Rhizoma,Chuanxiong Rhizoma,Notoginseng Radix et Rhizoma,Astragali Radix,Angelicae Sinensis Radix,Carthami Flos,Glycyrrhizae Radix et Rhizoma,Ginseng Radix et Rhizoma,Borneolum Syntheticum,and Corydalis Rhizoma.High-frequency drugs included blood-activating and stasis-resolving drugs(1 197,18.17%) and deficiency-tonifying drugs(809,12.28%).Cluster analysis identified eight drug combinations,including five new prescriptions suitable for clinical use and new drug development,and three drug pairs.The core drug combination of Salviae Miltiorrhizae Radix et Rhizoma-Chuanxiong Rhizoma-Carthami Flos was identified through the complex co-occurrence network analysis of Chinese medicines.Association rule analysis yielded a total of 17 rules,including 13 drug pairs and 4 tripartite combinations.Common drug pairs included Salviae Miltiorrhizae Radix et Rhizoma-Chuanxiong Rhizoma(support degree 25.79%,confidence coefficient 69.49%,lift 1.30) and Salviae Miltiorrhizae Radix et Rhizoma-Notoginseng Radix et Rhizoma(support degree 22.01%,confidence coefficient 61.95%,lift 1.16).Common tripartite combinations included Salviae Miltiorrhizae Radix et Rhizoma-Chuanxiong Rhizoma-Astragali Radix(support degree 10.85%,confidence coefficient 73.40%,lift 1.37) and Salviae Miltiorrhizae Radix et Rhizoma-Chuanxiong Rhizoma-Notoginseng Radix et Rhizoma(support degree 10.69%,confidence coefficient 79.07%,lift 1.48).The results showed that the underlying pathogenesis of angina involved blood stasis obstructing the heart and Qi deficiency and blood stasis.The overall nature of the disease was characterized as asthenia in origin and sthenia in superficiality.In the prescription formulation,blood-activating and stasis-resolving drugs,such as Salviae Miltiorrhizae Radix et Rhizoma,Chuanxiong Rhizoma,and Carthami Flos were often used to resolve the excess manifestation,which were combined with tonifying drugs such as Astragali Radix,Angelicae Sinensis Radix,Glycyrrhizae Radix et Rhizoma,and Ginseng Radix et Rhizoma to reinforce the deficiency.The syndrome,pathogenesis,disease nature,and medication were consistent with clinical practice.Additionally,the new compound prescriptions and drug combinations derived from the multiple data mining in this study could provide references and insights for the clinical diagnosis and treatment of angina and the development of new drugs.
作者
陈成笙
景康
郭艳蒙
牛玲
胡傲然
张明玺
CHEN Cheng-sheng;JING Kang;GUO Yan-meng;NIU Ling;HU Ao-ran;ZHANG Ming-xi(Hubei University of Chinese Medicine,Wuhan 430000,China;Wuhan Hospital of Traditional Chinese Medicine,Wuhan 430050,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2023年第20期5659-5667,共9页
China Journal of Chinese Materia Medica
基金
湖北省武汉市临床医学科研项目(WZ22C73)。
关键词
心绞痛
专利
中药复方
数据挖掘
用药规律
angina
patent
Chinese herbal compound
data mining
medication rules
